Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a randomized controlled trial
Santamaria A, Alibrandi A, Di Benedetto A, Pintaudi B, Corrado F, Facchinetti F, Di Vieste G, D'Anna R
Published in Menopause
Abstract
Study demonstrating 4g myo-inositol daily for 12 months significantly improved metabolic syndrome parameters including insulin sensitivity, blood pressure, and lipid profile in postmenopausal women.
Methodology
Randomised controlled trial of myo-inositol plus diet versus diet alone with metabolic syndrome components measured over 12 months.
Key Findings
In postmenopausal women with metabolic syndrome, myo-inositol 2 g twice daily improved insulin sensitivity (HOMA-IR), lowered triglycerides and diastolic blood pressure and raised HDL cholesterol compared with diet and lifestyle alone over 12 months.
Conclusions
Myo-inositol offers modest metabolic improvement as an adjunct to lifestyle change in postmenopausal metabolic syndrome, though the endpoints are biomarkers rather than clinical events.
Limitations
Open-label design with no placebo, single-centre Italian cohort, surrogate metabolic endpoints only, and modest sample size.
Supplements Studied
Myo-inositol improved metabolic syndrome parameters in postmenopausal women.
Outcomes Measured
In postmenopausal women with metabolic syndrome, myo-inositol 2 g twice daily improved insulin sensitivity (HOMA-IR), lowered triglycerides and diastolic blood pressure and raised HDL cholesterol compared with diet and lifestyle alone over 12 months.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported; investigators have prior relationships with inositol manufacturers
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.